Strides Pharma Science Completes US-FDA Inspection at Bangalore Facility
Strides Pharma Science Limited reported that its flagship facility located in Bangalore underwent a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection period spanned from May 12, 2026, to May 20, 2026.Following the USFDA's assessment, the company noted that a Form 483 was issued, detailing five observations.
Strides Pharma Science Limited confirmed that it will prepare a formal response to these observations within the time stipulated by the USFDA. The company stated it will provide further updates on the matter should any developments occur.
STAR Stock Price Movement
On Wednesday, shares of Strides Pharma Science Limited shed 0.75%, closing the session at ₹1141.7. The equity saw notable activity, trading on a volume of 644,863 shares throughout the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.